Bradykinin causes the release of vascular endothelial growth factor, which in turn would stimulate angiogenesis [13,14], and also indirectly affects lung cancer as it acts as a promoter of permeability of the vessels, by activating matrix metalloproteinase, which in turn leads to tumor invasion and metastases [14]. Here, KNG1 is linked to lung cancer.